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In this issue, Hommels et al. reported a study on a possible 
relationship between the Asp299Gly polymorphism in 
the Toll-like receptor-4 (TLR-4) gene and advanced aortic 
atherosclerosis.1 They did not find a significant relationship 
in their study, although others have reported a protective 
effect.2,3 The authors comment that the conclusion of their 
study should be taken with caution because of the small 
number of subjects. The study raises the question whether 
small studies are useful to study the relationship between 
common polymorphisms and disease.
First of all, I would like to stress the enormous advantage 
of genetics in the search for causes of disease. Although 
the relationship between inflammation and cardiovascular 
disease has been known for many years, nongenetic 
observational epidemiological studies are hampered 
by confounding and reverse causality. For instance, if 
somebody does find a relationship between C-reactive 
protein (CRP) and cardiovascular disease in a case-control 
study, the question arises whether this relationship could 
be explained by an increase in CRP through cardiovascular 
disease or vice versa. Moreover, several other factors could 
explain such a relationship through confounding. Using 
the concept of Mendelian randomisation, Davey Smith and 
Ebrahim eloquently describe the advantages of the use of 
genetic determinants instead of plasma markers.4 Besides 
this conceptual advantage, using genetic determinants 
also has some practical advantages. When DNA is isolated, 
many genetic determinants are easily available via high 
throughput facilities and genetic measurements are less 
influenced by storage conditions compared with the 
measurement of plasma markers. However, an important 
drawback of genetic studies is that in complex disease the 
effect of a single polymorphism is usually small and often 
dependent on the genetic and environmental background it 
is evaluated in. This requires not only an adequate sample 
size but also an adequate study design.
s T U d Y  d E s i G N
The study of the effect of a polymorphism on the incidence 
of a certain disease requires an effect measure which could 
be defined as the ratio between a difference in a certain 
determinant (X) and the difference in a certain outcome 
(Y). In case of the study on TLR-4 and atherosclerosis, one 
would like to know whether a change in TLR-4 activity is 
accompanied by a change in (incidence of) atherosclerosis 
(figure 1).
In fact, such a study could start with a contrast in X 
or with a contrast in Y. In other words one could start 
by recruiting a group of people that show a contrast 
in atherosclerosis and look for TLR-4 activity, or vice 
versa. Hommels et al. started their study with a group of 
patients with hypertension who underwent scanning of the 
abdominal aorta. The question is whether the contrast in 
atherosclerosis is comparable with a case-control study as 
carried out by Ameziane et al. who studied patients with 
vascular disease on the one hand and healthy subjects 
(hospital employees and blood donors) on the other.3
figure 1. The reliability of effect estimation of 
a possible relation between TLR-4 activity and 
atherosclerosis depends on the contrasts in X (TLR-4 
activity) or in Y (atherosclerosis)
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The contrast in atherosclerosis may be smaller when 
all patients have hypertension, which is a risk factor for 
atherosclerosis. In fact the authors made a comparison 
between subjects with advanced aortic atherosclerosis and 
less advanced aortic atherosclerosis.
Figure 1 shows that a comparison between subjects with 
vascular disease and a healthy population shows the 
strongest contrast. However, if a certain effect is found 
one is not sure that it is an effect of the determinant on the 
occurrence of disease or on the occurrence of healthiness. 
Therefore, it is recommended to take the control group 
from the general population. 
A second point is the contrast in X. The hypothesis is that 
a change in TLR-4 activity is accompanied by a change 
in atherosclerosis. Because TLR-4 activity is difficult to 
measure, the authors measured the Asp299Gly TLR-4 
polymorphism, which is a genetic determinant of TLR-4 
activity. This is a meaningful approach, which is in some 
ways better than measuring TLR 4 activity, because 
studies that use genetic determinants are less prone to 
confounding. However, only the wild-type and heterozygote 
genotypes were found. The question is whether there 
is enough contrast between wild-type and heterozygote 
genotype in TLR-4 activity.5 If there is no difference in TLR-4 
activity in wild-type and heterozygotes, the estimation of 
effect will strongly tend to no effect.
A third point is the question of confounding. Hommels et 
al. presented an uncorrected odds ratio. As stated before, 
studies that use polymorphisms as determinants are 
less prone to confounding than studies that use plasma 
markers. Therefore, the unadjusted estimate could be 
regarded as a good measure of effect. However, this does 
not rule out confounding. As shown in their table there are 
big differences in age. Therefore I would recommend also 
presenting adjusted odds ratios. This is comparable with 
the case of randomised trials with an uneven distribution 
of covariates. Randomisation should in theory result in 
an equal distribution of covariates, but if it does not this 
could allow confounding to occur. Another advantage of 
adjustment for age is that this would increase the contrast 
in atherosclerosis, which is strongly age dependent.
s A M P l E  s i Z E
The fourth point is on numbers. A genetic study of 123 
subjects with a polymorphism that is supposed to give at 
the most a small effect is at least underpowered to find a 
significant effect. However, one should keep in mind that 
the point estimate of effect is not influenced by the sample 
size. Whether it is useful to publish the results of small 
studies is a matter of debate. 
In a recent study Morgan et al. tried to validate the 
effects of multiple genes on atherosclerosis.6 The authors 
screened the literature and found 96 polymorphic genetic 
variants in 75 genes that were positively associated 
with atherosclerosis. They subsequently screened 85 
polymorphisms in 70 genes. Using appropriate statistical 
techniques, including correction for multiple testing, they 
did not find a positive correlation between any of the tested 
genes and the risk of atherosclerosis. This study nicely 
illustrates the drawbacks of this type of research.
A lot of small studies taken together make a big one. 
The question is whether such pooled analysis suffers 
from bias because journals tend not to publish ‘negative’ 
results. Recently, Borm et al. showed that publication 
bias is not a serious issue in meta-analysis of trials and it 
could be argued that the same holds for studies on genetic 
determinants of disease.7 It could be argued that the same 
holds for studies on genetic determinants of disease, 
although it has been demonstrated that molecular genetic 
research is more sensitive to publication bias than clinical 
trials.8 
In conclusion, I don’t argue that we should stop publishing 
small studies, but it is important to be very reserved in 
the conclusions based on such small studies, whether 
‘negative’ or ‘positive’- as is done in the paper of Hommels 
et al. Firm conclusions should be based on multiple, large-
scale studies.
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